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EARLY ONSET URTICARIA – A MARKER OF CRYOPYRIN ASSOCIATED 
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A one-year-old boy presented with an asymptomatic fleeting erythematous rash, recurring 
since 6 hours after birth, without fever and poorly responsive to high-dose antihistamines. 
The lesions, which disappeared within hours, appeared when he was undressed or bathed, 
suggesting cold as a trigger. He was otherwise well, growing and developing normally, with 
no relevant personal or family history. Examination showed multiple small scattered 
urticarial rash on his trunk and extremities (Fig. 1).  
Investigations revealed low haemoglobin 109 g/L (117-137), raised white blood cells 19.6 
x10
9
/L (5.0-16.0), platelets 512 x10
9
/L (150-400), CRP 32 mg/L (0-10) and ESR  85 mm/hr 
(0-9).  Other than a slightly low IgD 0.03 g/L (0.05-0.20), immunoglobulins were within 
normal limits. Histology from a representative lesion showed a neutrophilic urticarial 
dermatosis characterised by perivascular and interstitial neutrophilic infiltrate with 
leukocytoclasia but without vasculitis or dermal oedema (Fig. 2). 
These findings prompted further investigations which demonstrated a raised serum amyloid 
A protein at 15.5 mg/L (<5-10mg/L) and a previously described pathogenic heterozygous 
mutation in exon 3 of NLRP3, Asp303Asn (D303N), which was absent in his parents and 
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siblings, signalling a diagnosis of cryopyrin associated periodic syndrome (CAPS). Treatment 
with anakinra led rapidly to complete resolution of the symptoms and serological 
abnormalities, and he remains well at 2.5 years of age.  
CAPS, sometimes termed the cryopyrinopathies, is an hereditary periodic fever syndrome 
caused by dominantly inherited or de novo gain-of-function mutations in the NLRP3 gene 
located on chromosome 1q44, which encodes the intracellular protein cryopyrin (formerly 
NALP3).  Activation of cryopyrin, a constituent of the multiprotein inflammasome complex, 
results in downstream activation of caspase 1 leading to over-production of interleukin IL-1ß, 
a potent inflammatory cytokine that drives the characteristic fever, vasodilation and systemic 
inflammation.
1
   
Three subtypes of CAPS are recognised but there is considerable clinical as well as genetic 
overlap. Familial cold autoinflammatory syndrome (FCAS) is the mildest variant with cold-
induced episodes of fever with rash, arthralgia, headaches and occasionally conjunctivitis. In 
Muckle-Wells syndrome (MWS) there is additionally, but variably, sensorineural hearing loss 
and amyloidosis in adulthood (25%). Neonatal-onset multisystem inflammatory disease 
(NOMID)/chronic infantile neurologic, cutaneous, articular syndrome (CINCA) is the most 
severe form with about 20% mortality before adulthood. It presents in the neonate or infant 
with spontaneous urticarial rash and fever; later patients develop central nervous symptoms, 
sensorineural hearing loss, ocular changes (80%) and disabling arthropathy.
2
 Although the 
course of CAPS is unpredictable, sporadic occurrence, early onset (<6 months), and urticaria 
not provoked by cold are associated with a higher risk of severe neurological complications.
3
    
The relatively mild presentation and provocation by cold in our patient are in keeping with 
the FCAS end of the CAPS spectrum, but the very early onset is a concern. Furthermore, the 
D303N mutation in NLRP3 gene has been reported in association with MWS and CINCA but 
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not FCAS.
2,4
 It is not possible to accurately predict the risk of neurological complications and 
neurosensory hearing loss in a young patient with CAPS, since the precise features severity 
of the disease may vary substantially within a single family, let alone among the numerous 
different causative mutations. Cold trigger and autosomal dominant inheritance have been 
reported as predictors of better prognosis, but All these patients require close long term 
monitoring including audiometry, ophthalmology and neurological review and early IL-1 
blocking treatment to minimize the risk of long-term complications.
3
 
Our case highlights the importance of considering autoinflammatory syndromes when a child 
presents with very early onset, asymptomatic, fleeting urticarial lesions, unresponsive to 
antihistamines, even without other features of systemic inflammation. A perivascular 
neutrophilic infiltrate on histology supports a diagnosis of CAPS. Prompt diagnosis allows 
the use of specific treatment with anti-IL-1 agents,
5
 which dramatically improves quality of 
life in most cases and hold great hope for improving outcomes long-term. 
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Figure Legends: 
Figure 1:   Multiple scattered urticarial rash on the lower limbs 
Figure 2: Histopathology from a representative lesion showing perivascular and 
interstitial neutrophilic infiltrate with leukocytoclasia but without vasculitis or dermal 
oedema. Haematoxylin and eosin, original magnification x 400 
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Histopathology from a representative lesion showing perivascular and interstitial neutrophilic infiltrate with 
leukocytoclasia but without vasculitis or dermal oedema. Haematoxylin and eosin, original magnification x 
400  
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MCQs: 
Learning objective 
To demonstrate up-to-date knowledge in the pathogenesis of cryopyrin associated period 
syndrome. 
Question 1 
1. Mutation in which of the following genes causes cryopyrin associated periodic syndrome?  
a) MEFV 
b) MVK 
c) IL1RN 
d) NLRP3 
e) IL36RN 
Answers to question 1: 
a) Incorrect, mutation in MEFV gene causes familial mediterranean fever 
b) Inorrect, mutation in MVK gene causes Hyperimmunoglobulinemia D with Periodic Fever 
Syndrome (HIDS)or Mevalonate Aciduria (MA) 
c) Incorrect, mutation in IL1RN gene is implicated in Deficiency of Interleukin-1ß (IL-1ß) 
Receptor Antagonist (DIRA)  
d) Correct, mutation in NLRP3 gene causes cryopyrin associated periodic  
e) Incorrect, mutation in IL36RN is implicated in Deficiency of Interleukin-36-Receptor 
Antagonist (DITRA) 
Question 2: 
Learning objective: To demonstrate up-to-date knowledge in the management of cryopyrin 
associated period syndrome. 
The drugs used in the treatment of cryopyrinopathies are targeted against which of the 
following interleukins? 
a) IL-6 
b) IL-8 
c) IL-5 
d) IL-1 
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e) IL-17 
Answers to Question 2: 
a) Incorrect. The drugs targeted against IL-6 are used in treatment of certain rheumatic 
disease such as Castleman’s disease and rheumatoid arthritis.  
b) Incorrect. The drugs used in treatment of cryopyrinopathies are not targeted against IL-8  
c) Incorrect. The drugs targeted against IL-5 are tried in the treatment of eosinophilic 
disorders. 
d) Correct. The drugs such used in treatment of cryopyrinopathies are targeted against IL-1  
e) Incorrect. The drugs targeted against IL-17 are used in psoriasis  
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